Flow Cytometry Market

Flow Cytometry Industry Outlook (2022-2032)

The global Flow Cytometry market is likely to be valued at US$ 6.1 Billion in FY 2022, up from US$ 5.3 Billion in 2021. During the past year, the industry registered a Y-o-Y increase worth ~11%. From 2022 to 2032, Flow Cytometry sales are poised to flourish at a CAGR of 11.1% to reach a value of US$ 16.7 Billion by the end of 2032.

Report Attributes	Details
Anticipated Base Year Value (2021)	US$ 5.3 Billion
Expected Market Value (2022)	US$ 6.1 Billion
Projected Forecast Value (2032)	US$ 16.7 Billion
Global Growth Rate (2022-2032)	11.1% CAGR
Growth Rate of the U.S Market (2022-2032)	8.1% CAGR
Expected Market Value of China (2032)	US$ 3.9 Billion
U.K Market Expansion Rate (2022-2032)	~11% CAGR
Key Companies Profiled	Becton Dickinson & Company Merck & Co. Inc. Beckman Coulter Inc. Thermo Fisher Scientific Inc. SYSMEX CORPORATION Alere Inc. Miltenyi Biotec Bio-Techne Corporation Agilent Technologies Inc. Bio-Rad Laboratories Inc.

Demand for flow cytometry services will continue to thrive, with a documented CAGR of 6% during the 2015-2021 historical period of assessment, while demand for Flow Cytometry in pharmaceutical & drug discovery proliferated at a rate of 7.2% during the same time period. North America will dominate the global market, registering a growth opportunity worth US$ 10.2 Billion from 2022 to 2032.

2015 to 2021 Flow Cytometry Market Revenue Analysis vs. Market Outlook 2022-2032

Fact.MR has forecasted the Flow Cytometry market to rise at 11.1% CAGR between 2022 and 2032 in comparison to the 11% CAGR during 2015 -2021. Extensive uptake for pharmaceutical & drug discovery and diagnostics have typically influenced historical growth.

Manufacturers are capitalizing on discovering the treatments for chronic diseases like cancer, thereby the demand for flow cytometry is likely to upsurge over the forecast period.

Key Drivers Stimulating Flow Cytometry Industry Expansion

Future expansion prospects will largely be driven by the escalating scope of immunology and oncology research

Swelling developments on the technological front and the growing occurrence of chronic diseases that require validation testing and the need for precise and delicate techniques for disease validation are some of the key drivers of the flow cytometry market. Researchers are increasingly using flow cytometry to qualitatively and quantitatively analyze peripheral blood cells to predict immunotherapy outcomes. The flow cytometry market is principally influenced by high resolution, improved efficiency, and the expansion of efficient statistical platforms.

In terms of opportunity, the market observed substantial growth in the bioengineering segment and its applications in various fields such as drug discovery, cell culture, and stem cell therapy. Additionally, the soaring demand for rapid and precise cancer prognostic tools combined with the soaring prevalence of infectious diseases is expected to prompt market growth.

Generally, broadened demands for mounting applications in the life science industry are expected to boost the demand market. The upsurge in several healthcare organizations that encourage the usage of high-quality treatment and medical procedures is more likely to result in the development of the market.

Key Challenges to Flow Cytometry Industry Expansion

High Cost & Lack of Awareness Act as a Prominent Restraining Factor

Increasing prevalence rates of chronic diseases such as cancer and HIV are expected to boost the acceptance of flow cytometry technology across diagnostic applications. On the other hand, factors such as expensive costs associated with instruments and reagents, lack of awareness amongst potential end-users, and the inadequate availability of technical expertise are expected to obstruct the flow cytometry market growth.

Country-wise Analysis

How Opportunistic are Growth Prospects across the U.S Market?

North America Witnessed Highest Rev up in Sales Revenue in 2022

Fact.MR’s latest analytical report reveals that the North American region dominates the flow cytometry market and accounts for nearly 1/3rd contribution in the global revenue. As per the report, the U.S market is projected to yield a dollar opportunity of US$ 10.2 Billion, following a CAGR of 8.1% throughout the forecast period. A high level of demand exists in North American markets for flow cytometry devices.

Rapid technological advancements have contributed to an increase in market valuation. As chronic diseases are becoming more prevalent, research and technology in cell sorting have increased the demand for flow cytometry in these markets. For instance, Sysmex Corporation launched flow cytometry XF-1600 in North American markets. On June 17th, 2020, the firm launched the PS-10 sample preparation system that automates sample preparation and offers a range of analyte-specific options through Sysmex in the US.

The growing understanding of immunologic forces regulating systemic diseases, as well as the development of molecular diagnostics, monoclonal antibodies, lasers, and IT, will have a profound impact on flow cytometry and hematology in the North American markets.

Why are Flow Cytometry Providers Venturing into China?

APAC Region Registers the Fastest Growth Rate in Flow Cytometry Industry

Asia promises to exhibit a robust expansion trajectory, clocking a staggering 14% CAGR from 2022 to 2032. Fact.MR forecasts that the valuation for the flow cytometry market is likely to reach US$ 3.9 Billion by 2032 end. Improvements in healthcare infrastructure, particularly across India and China, are prompting global pharmaceutical companies to invest in the regional flow cytometry industry.

Furthermore, surging incidences of hematological and immunological diseases are also widening growth prospects. A study published in 2019 established those autoimmune diseases incidence has increased manifold, with 75% of those affected being women. Hence, flow cytometry to prevent further deterioration is inclining across the region.

Country-wise Value CAGRs for Flow Cytometry (2022-2032)

U.S	8.1%
U.K	11%
China	14%
Japan	14.1%
South Korea	13.4%

Category-wise Insights

Which Type of Product & Services is Most Preferred in the Flow Cytometry Market?

Flow Cytometry Software Have Gained Huge Traction in Recent Years

In terms of market revenue, the Flow cytometry software & services segment contributes over 40% share of the global revenue collection. The demand for flow cytometry software is forecast to expand at an annual rate of 6% throughout the conjecture period.

As technology advances, the demand for software is on the rise in the medical industry. The increasing demand for advanced software that can be used with these devices is due to the increasing desire to view the cells and examine them simultaneously during the analysis.

For instance, NovoExpress Software enables scientists of all experience levels to acquire and analyze data efficiently. By automating many fluidic functions, the software eliminates time-sucking and cumbersome procedures. This software is flexible, intuitive, and versatile in nature.

By Application, which Flow Cytometry is expected to Dominate?

Drug discovery and development is a very complex, lengthy, and expensive process. As a tool to identify and characterize drug-induced toxicity in animal models and cell culture systems, flow cytometry has been used for a drug safety assessment with multiple benefits for biomedical research.

Flow cytometry allows measurement of acute or subacute toxic effects, as well as the detection of cancerous, mutational, and cancer-causing effects in tissue samples or cultured cells. These devices are used in preparing single-cell suspensions of tissue samples in a homogeneous or dissociated state, which allows the study of the preclinical toxicity of drugs on any tissue sample. Fact.MR predicts that a market share of 45% is projected for this segment.

Competitive Landscape

Prominent Flow Cytometry providers are reliant on partnerships, collaborations, acquisitions, and new software launches so as to stay afloat in the global market. Constant innovations to ensure a seamless client-customer relationship are the main focus of prominent market players.

• In April 2020, Merck, a leading science and technology company, launched its new CellStream™ benchtop flow cytometry system, a compact, customizable flow cytometer that uses a camera for detection. Its unique optics system and design provide researchers with unparalleled sensitivity and flexibility when analyzing cells and submicron particles.
• In July 2021, Thermo Fisher Scientific Inc. TMO recently announced the launch of Thermo Scientific Phenom Pharos G2 Desktop Field Emission Gun -- Scanning Electron Microscope (FEG-SEM). The instrument is designed to accelerate access to advanced nanomaterial research capabilities.
• The Phenom Pharos G2 advances nanomaterial research by delivering high resolutions and a broad acceleration voltage range, all in a desktop system that can fit within a lab or office.

Key Segments Covered in the Flow Cytometry Industry Survey

• By Technology

  • Cell-based Flow Cytometry
  • Bead-based Flow Cytometry

• By Products & Services

  • Flow Cytometry Reagents & Consumables
  • Flow Cytometry Instruments
  • Flow Cytometry Software
  • Flow Cytometry Services

• By Application

  • Flow Cytometry for Pharmaceutical & Drug Discovery
  • Flow Cytometry for Diagnostics
  • Flow Cytometry for Other Applications

• By End-User

  • Flow Cytometry for Hospitals & Diagnostic Labs
  • Flow Cytometry for Academic & Research Institutions
  • Flow Cytometry for Other End Users

• Flow Cytometry by Region

  • North America Flow Cytometry Market
  • Latin America Flow Cytometry Market
  • Europe Flow Cytometry Market
  • Asia Pacific Flow Cytometry Market
  • Middle East & Africa Flow Cytometry Market